Drugs / EOC317
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03583125 | May 2018 → Feb 2020 | cancer | Taizhou EOC Pharma Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-08-09 | Taizhou EOC Pharma Co., Ltd. | Results 亿腾景昂药业抗肿瘤新药EOC317完成首例患者给药 eocpharma.com ↗
目前第一例患者已经完成剂量限制性毒性观察期，初步研究结果显示，此剂量组的EOC317具有良好的安全性和耐受性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-09 | Taizhou EOC Pharma Co., Ltd. | 亿腾景昂药业抗肿瘤新药EOC317完成首例患者给药 eocpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EOC317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03583125 ↗ |
| Route | Oral | “tablet(s) PO” NCT03583125 ↗ |